 |
1 Company | 1 Product |
|
|
1 Product | |
19 Diseases | |
1 Trial |  |
19 News |  |
| 12345678910111213...3031» |
- | Journal: Analysis of global gene expression using RNA-sequencing reveals novel mechanism of Yanghe Pingchuan decoction in the treatment of asthma. (Pubmed Central) - Mar 23, 2024
Control of asthma pathogenesis by YPD may be related to inhibition of the Ang-II/PLA/CaM signaling axis, reduction of the Ca2+ concentration, and relaxation of airway smooth muscle (ASM).
- | Journal, IO biomarker: ANGPT1 promotes M1 macrophage polarization and inhibits lung adenocarcinoma progression by inhibiting the TGF-? signalling pathway. (Pubmed Central) - Mar 17, 2024
signalling pathway. Thus, ANGPT1 could be employed as a predictive biomarker and immunotherapy target for lung cancer.
- tamoxifen / Generic mfg.
INHIBITION OF ANGIOPOIETIN-2 COMBINED WITH A HIGH LEVEL OF ANGIOTENSIN-II EXACERBATES RENAL FIBROSIS (MON-077; Exhibition Hall and Main Foyer) - Mar 8, 2024 - Abstract #ISNWCN2024ISN_WCN_810;
exacerbates kidney fibrosis. Further studies are required to investigate the specific cellular components and the underlying pathogenic mechanisms involved in this process.
- | Journal: Therapeutic inhibition of angiopoietin-like protein 3 for hypertriglyceridaemia and residual risk of ASCVD: beginning of the end or end of the beginning? (Pubmed Central) - Mar 6, 2024
Further studies are required to investigate the specific cellular components and the underlying pathogenic mechanisms involved in this process. No abstract available
- | Journal: Inhibiting angiopoietin-like protein 3: clear skies or clouds on the horizon? (Pubmed Central) - Mar 4, 2024
No abstract available No abstract available
- | Journal: Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic risk. (Pubmed Central) - Mar 4, 2024
PTVs influencing ANGPTL3 protein structure as well as common genetic variants influencing ANGPTL3 hepatic expression and/or blood protein levels exhibit a strong effect on circulating plasma triglyceride levels, a weak effect on circulating apoB levels, and no effect on ASCVD. Near-complete inhibition of ANGPTL3 function in patients with very elevated apoB levels may be required to reduce ASCVD risk.
- | Journal: Endothelial lipase variant T111I does not alter inhibition by angiopoietin-like proteins. (Pubmed Central) - Feb 25, 2024
Moreover, we found no difference between wild-type and T111I EL in their ability to be inhibited by ANGPTL proteins. These data suggest that any effect this variant may have on HDL-C levels or cardiovascular disease are not mediated through alterations in these functions.
- || Review, Journal: Inhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia. (Pubmed Central) - Jan 8, 2024
Inhibition of ANGPTL3 or the ANGPTL3/8 complex upregulates LPL and facilitates the hydrolysis and clearance of triglyceride-rich lipoproteins (TRL) (LPL-dependent mechanisms), whereas ApoC-III inhibitors contribute to the management and clearance of TRL through both LPL-dependent and LPL-independent mechanisms making it possible to successfully lower TG in subjects completely lacking LPL (familial chylomicronemia syndrome). Most of these agents are biologicals including monoclonal antibodies (mAb), antisense nucleotides (ASO), small interfering RNA (siRNA), or CRISPR-cas gene editing strategies.
- ||| Vabysmo (faricimab-svoa) / Roche
P3 data, Journal: Faricimab Treat-and-Extend for Diabetic Macular Edema: 2-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials. (Pubmed Central) - Jan 2, 2024
P3
Clinically meaningful visual acuity gains from baseline, anatomic improvements, and extended durability with intravitreal faricimab up to Q16W were maintained through year 2. Faricimab given as a personalized T&E-based dosing regimen supports the role of dual angiopoietin-2/VEGF-A inhibition to promote vascular stability and provide durable efficacy for patients with DME.
- | Vabysmo (faricimab-svoa) / Roche
Journal: Intravitreal faricimab as an adjuvant in the management of tubercular uveitis. (Pubmed Central) - Dec 20, 2023
Intravitreal faricimab, given its angiopoietin-2 (ang2) inhibition and anti-vascular endothelial growth factor action, maybe a helpful adjunct in IOTB. Whether ang2 inhibition provides any additional benefit needs further evaluation in extensive studies.
- || Review, Journal: New biological therapies for low-density lipoprotein cholesterol. (Pubmed Central) - Dec 17, 2023
Vaccines and gene editing therapies in particular hold great potential to potentially confer active long-term or provide single-treatment life-long knock-down of PCSK9 or ANGPTL3 activity. Biologic therapies inspired by monogenic hypocholesterolemia states are becoming valuable tools to help protect against atherosclerotic cardiovascular disease.
- | Biomarker, Journal, Tumor microenvironment: Attenuating epithelial-to-mesenchymal transition in cancer through angiopoietin-like 4 inhibition in a 3D tumor microenvironment model. (Pubmed Central) - Nov 21, 2023
Suppression of Angptl4 using antisense oligonucleotides or anti-cAngptl4 antibodies led to a dose-dependent abolishment of EMT-mediated chemoresistance and tumor self-organization in 3D, ultimately resulting in diminished metastatic potential and stunted growth of tumor xenografts. Our unique programmable 3D cancer cultures simulated stiffness levels in the tumor microenvironment and unveiled Angptl4 as a promising therapeutic target to inhibit EMT and impede cancer progression.
- | ARO-ANG3 / Arrowhead, vupanorsen (AKCEA-ANGPTL3-LRx) / Ionis, Pfizer
Journal: Angiopoietin-like 3 inhibition and the liver: less is more? (Pubmed Central) - Nov 3, 2023
An alternative explanation may relate to off-target effects of vupanorsen, which have a molecule- and/or platform-specific origin. For intrahepatic strategies, highly potent ANGPTL3 inhibition will for now require special attention for liver safety.
- Vabysmo (faricimab-svoa) / Roche
Automated Segmentation of Hyperreflective Foci in DME: Greater Volume Reduction With Faricimab in Phase 3 YOSEMITE/RHINE (DEMAND) - Oct 28, 2023 - Abstract #AAO2023AAO_2262;
P2, P3
At 3-mm diameter, corresponding values from BL to Week 48 were greater for FAR q8w (?406.76 pL) and FAR T&E (?533.01 pL) versus AFL (?397.67 pL; P = .0142 and P = .0034, respectively). Conclusion Greater retinal HRF volume reductions with FAR versus AFL support the therapeutic potential of dual angiopoietin-2/VEGF-A inhibition to suppress disease activity in DME.
- | Journal: Long-term physical activity modulates adipsin and ANGPTL4 serum levels, a potential link to exercise-induced metabolic changes. (Pubmed Central) - Oct 22, 2023
Interestingly, this interrelationship was not detectable after eight months of physical training. This finding might indicate adipsin's involvement in linking triglyceride-balance to individual performance and energy demands in a homeostatic state.
- | Observational data, Journal: Peak torque angle, acceleration time and time to peak torque as additional parameters extracted from isokinetic test in professional soccer players: a cross-sectional study. (Pubmed Central) - Oct 22, 2023
CB, CDM and CAM extensors of the NDL showed higher PT, TW and Pw than DL (p < 0.05). In conclusion, there are muscle imbalances between limbs in SB, CDM and CAM and across different field positions.
- ||| Vabysmo (faricimab-svoa) / Roche
Clinical, P3 data, Journal: BALATON and COMINO: Phase III Randomized Clinical Trials of Faricimab for Retinal Vein Occlusion: Study Design and Rationale. (Pubmed Central) - Oct 9, 2023
P3
Using a novel automated interval algorithm, BALATON/COMINO will evaluate the efficacy and safety of faricimab for ME secondary to RVO and provide key insights into how to personalize treatment. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
- || Review, Journal: The evolving therapeutic landscape of diabetic retinopathy. (Pubmed Central) - Aug 14, 2023
These strategies hold promise for early and long-lasting treatment of DR. The evolving therapeutic landscape of DR is rapidly expanding our toolkit for the effective and durable treatment of blinding eye disease, but further research is required to validate the efficacy of novel therapeutics and characterize real world outcomes.
- Evkeeza (evinacumab-dgnb) / Regeneron, Ultragenyx, Sanofi
Effects of Evinacumab on Atherogenic Lipoproteins in Children and Adolescents From Ages 5 to 17 Years With Homozygous Familial Hypercholesterolemia (Zone 3, Science and Technology Hall, Level 2) - Aug 12, 2023 - Abstract #AHA2023AHA_6127;
P3
Evinacumab strikingly and comparably reduces atherogenic lipids in younger and older pediatric HoFH patients. Since standard LLT rarely lowers LDL-C levels to treatment goals in pediatric HoFH, evinacumab should be strongly and urgently considered in these patients whenever further LDL-lowering is needed after optimizing standard LLT.
- || Review, Journal: Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events. (Pubmed Central) - Aug 12, 2023
Beyond statins and ezetimibe, different medications targeting LDL-C have been recently approved by regulatory agencies with potential innovative mechanisms of action, including proprotein convertase subtilisin/kexin type 9 modulators (monoclonal antibodies such as evolocumab and alirocumab; small interfering RNA molecules such as inclisiran), ATP-citrate lyase inhibitors (bempedoic acid), angiopoietin-like 3 inhibitors (evinacumab), and microsomal triglyceride transfer protein inhibitors (lomitapide). An understanding of their pharmacological aspects, benefit-risk profile, including impact on hard cardiovascular endpoint beyond LDL-C reduction, and potential advantages from the patient perspective (e.g., adherence) - the focus of this evidence-based review - is crucial for practitioners across medical specialties to minimize therapeutic inertia and support clinical practice.
- || Vabysmo (faricimab-svoa) / Roche
Review, Journal: Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema: Lessons Learned from Registration Trials. (Pubmed Central) - Jul 6, 2023
An understanding of their pharmacological aspects, benefit-risk profile, including impact on hard cardiovascular endpoint beyond LDL-C reduction, and potential advantages from the patient perspective (e.g., adherence) - the focus of this evidence-based review - is crucial for practitioners across medical specialties to minimize therapeutic inertia and support clinical practice. Faricimab demonstrated non-inferior to superior efficacy, strong durability and acceptable safety in treatment-na
- | Evkeeza (evinacumab-dgnb) / Regeneron, Ultragenyx
Journal: Individualized dosing of evinacumab is predicted to yield reductions in drug expenses. (Pubmed Central) - Jun 19, 2023
Dose reductions without compromising efficacy seem feasible. We call for implementation and prospective evaluation of this strategy to reduce treatment costs of HoFH.
- Essential Roles Of Prdm16 In Repression Of Venous Marker In The Artery (Gloucester/Back Bay, 3rd Floor) - Jun 13, 2023 - Abstract #VASCULARDISCOVERY2023VASCULAR_DISCOVERY_521;
Conversely, forced expression of Prdm16 in venous ECs is sufficient to induce arterial gene expression and repress ANGPT2 level. Together, these results reveal an arterial cell-autonomous function for PRDM16 in suppressing venous characteristics in arterial ECs.
- || Evkeeza (evinacumab-dgnb) / Regeneron, Ultragenyx
P2 data, Journal: Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial. (Pubmed Central) - Mar 25, 2023
P2
Although the primary end point of a reduction in triglycerides did not meet the prespecified significance level, the observed safety and changes in lipid and lipoprotein levels support the further evaluation of evinacumab in larger trials of patients with sHTG. Trial registration number: ClinicalTrials.gov NCT03452228 .
- | Evkeeza (evinacumab-dgnb) / Regeneron, Ultragenyx
Journal: Angiopoietin-like proteins inhibitors: New horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia. (Pubmed Central) - Mar 4, 2023
The use of evinacumab in clinical trials also led to the normalization of plasma lipid concentrations in patients with atherogenic dyslipidemia and homozygous familial hypercholesterolemia. The results of these studies indicate that evinacumab may in the future be used in the treatment of lipid disorders, especially those with hypertriglyceridemia.
- || trebananib (AMG 386) / Amgen, BI 836880 / Boehringer Ingelheim, Avastin (bevacizumab) / Roche
PK/PD data, Journal: Pharmacodynamic and Antitumor Activity of BI 836880, a Dual VEGF and Angiopoietin 2 Inhibitor, Alone and Combined with Programmed Cell Death Protein-1 Inhibition. (Pubmed Central) - Mar 2, 2023
Here, we show that BI 836880, a bispecific nanobody targeting VEGF and ANG2, demonstrates substantial antitumor activity in preclinical models. Combining VEGF/ANG2 inhibition with blockade of the PD-1 pathway can further improve antitumor activity.
- Vabysmo (faricimab) / Roche
Faricimab causes rapid and sustained intraocular suppression of angiopoietin-2 and VEGF-A for up to 16 weeks in neovascular age-related macular degeneration and diabetic macular edema (Fontainebleau - Miami, FL) - Jan 13, 2023 - Abstract #Macula2023Macula_272;
P2, P3
Combining VEGF/ANG2 inhibition with blockade of the PD-1 pathway can further improve antitumor activity. PopPKPD analyses demonstrated that intravitreal injection of faricimab leads to rapid and sustained suppression of AH Ang-2 and VEGF-A levels, with Ang-2 suppression through 16 weeks post dose, supporting the extended durability reported in the Phase 3 trials.
- Vabysmo (faricimab) / Roche
Durable Vision Gains and Greater Fluid Control With Extended Faricimab Dosing Up to Every 16-Week Over 2 Years of Phase 3 YOSEMITE and RHINE Trials in Diabetic Macular Edema (Fontainebleau - Miami, FL) - Jan 13, 2023 - Abstract #Macula2023Macula_108;
P3
With treat-and-extend–based dosing up to Q16W in YOSEMITE/RHINE, faricimab offered extended and stable durability together with vision gains and improved earlier fluid control that were maintained over 2 years. These Results support the potential for faricimab, via its novel mechanism of dual angiopoietin-2/VEGF-A inhibition, to reduce treatment burden for patients with DME compared with currently available anti-VEGF therapies.
- Evkeeza (evinacumab-dgnb) / Regeneron, Ultragenyx
APPLICATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL POLYGENIC RISK SCORE ANALYSIS IN PATIENTS WITH REFRACTORY HYPERCHOLESTEROLEMIA (Ischemic Heart Disease Moderated Poster Theater 7_Hall F) - Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_3877;
P2
Results confirm that genome-wide LDL-C PRS is a suitable method to stratify pts from the general population. However, in cohorts with extreme LDL-C, particularly those with refractory HC, LDL-C PRS analyses are of limited utility.
- ||||| Clinical: A case of the oldest living patients with homozygous familial #hypercholesterolemia. Angiopoietin-like 3 inhibitor therapy successfully lowered her #LDL-C. https://t.co/jVeZg27ROA #JACCCaseReports #CardioTwitter @SethShayMartin (Twitter) - Dec 19, 2022
- || Juxtapid (lomitapide) / Amryt, Novelion, Nexletol (bempedoic acid) / Esperion Therap, Otsuka, Daiichi Sankyo
Review, Journal: A stepwise approach to prescribing novel lipid-lowering medications. (Pubmed Central) - Dec 17, 2022
Several new lipid lowering medications have received approval by regulatory agencies in the past decade including proprotein convertase subtilisin/kexin type 9 modulators, ATP-citrate lyase inhibitors, angiopoietin-like 3 inhibitors, lomitapide, and icosapent ethyl...This information can help the clinicians to prescribing these novel lipid lowering medications to achieve treatment goals and reduce the risk of atherosclerotic cardiovascular disease. The aim is to shift the paradigm for high-intensity statins from watch and wait to initial combination therapy for high-risk patients.
- | Evkeeza (evinacumab-dgnb) / Regeneron, Ultragenyx
Journal, Real-world evidence: Long-Term Efficacy and Safety of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia: Real-World Clinical Experience. (Pubmed Central) - Nov 25, 2022
Evinacumab was well-tolerated, with no major adverse event reported or significant changes in liver and muscle enzyme concentrations. Our findings suggest that evinacumab is a safe and effective treatment for patients with HoFH receiving best standard of care in a routine setting.
- || BI 836880 / Boehringer Ingelheim
P1 data, Journal: Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors. (Pubmed Central) - Oct 25, 2022
P1
The MTD of BI 836880 was 720 mg Q3W and 180 mg QW. BI 836880 was generally manageable and demonstrated preliminary efficacy.
- DHX15 DEFICIENCY AFFECTS VASCULAR GROWTH AND IMPAIRS TUMOR PROGRESSION IN A MOUSE MODEL OF HEPATOCELLULAR CARCINOMA () - Oct 23, 2022 - Abstract #AASLD2022AASLD_1808;
DHX15 deficiency in Hepa 1-6 HCC model is associated with vascular alterations that impede proper vascular development in the primary tumor resulting in decreased primary tumor volume and reduced metastasis in the liver. Our findings reveal the regulatory function of DHX15 in controlling vascular organization, tumor growth and metastasis.
- Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
ACE Inhibition and GLP1 Receptor Agonism Have Direct Effects on the Glomerular Capillary Wall to Reduce Glomerular Albumin Permeability in Diabetes (Exhibit Hall, Orange County Convention Center, West Building) - Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_3588;
Conclusion Semaglutide and enalapril both ameliorate the diabetes-induced increase in P s’ alb , demonstrating a direct effect on the cells of the GFB in diabetes. Thus, a greater understanding of the mechanisms of glomerular protection mediated by these renoprotective compounds is needed to identify novel therapeutic strategies.
- | Journal: Targeting angiopoietin-2 as a novel treatment option for kidney fibrosis. (Pubmed Central) - Sep 30, 2022
Angiopoietin-2 inhibited the renoprotective effects of angiopoietin-1 and promoted CC chemokine ligand 2-mediated kidney damage, endothelial cell apoptosis, vascular rarefaction, inflammation, fibrosis, and kidney dysfunction. Hence, therapeutically inhibiting angiopoietin-2 may represent a novel means of treating these chronic kidney disease-associated pathologies.
- | Journal: Angiopoietin-2 inhibition attenuates kidney fibrosis by hindering chemokine C-C motif ligand 2 expression and apoptosis of endothelial cells. (Pubmed Central) - Sep 29, 2022
Based on this, we applied L1-10, an angiopoietin-2 inhibitor, to the mouse models of progressive kidney disease and found inhibitory effects on macrophage infiltration, microvascular rarefaction, and fibrosis. Thus, we defined the detrimental impact of increased angiopoietin-2 on kidney survival of patients with CKD which appears highlighted by angiopoietin-2 induced endothelial CCL2-activated macrophage infiltration and endothelial cell apoptosis in their kidneys undergoing fibrosis.
- Praluent (alirocumab) / Sanofi, Regeneron, Evkeeza (evinacumab) / Regeneron, Ultragenyx, Repatha (evolocumab) / Amgen, Astellas
Homozygous Familial Hypercholesterolemia: Luck Meets Opportunity Meets Knowledge (Virtual Only) - Aug 20, 2022 - Abstract #AHA2022AHA_6611;
We report a case of HoFH with successful lowering of LDL levels on dual antibody and high intensity statin therapy along with PIB. Unlike PCSK9 inhibitors, ANGPTL3 inhibitors work independently of LDLRs by stimulating lipoprotein & endothelial lipase.
- Vabysmo (faricimab) / Roche
Efficacy, Durability and Safety of Faricimab in DME: Two-Year Results From YOSEMITE and RHINE (S405) - Aug 8, 2022 - Abstract #AAO2022AAO_1347;
P3
Unlike PCSK9 inhibitors, ANGPTL3 inhibitors work independently of LDLRs by stimulating lipoprotein & endothelial lipase. Robust vision gains, anatomic improvements, and durability with FAR up to Q16W were maintained over 2 years.
- || Review, Journal: Macrotrabecular-Massive Hepatocellular Carcinoma: Light and Shadow in Current Knowledge. (Pubmed Central) - Aug 6, 2022
The MTM-HCC subtype is associated with various adverse biological and pathological parameters (the Alfa-foetoprotein (AFP) serum level, tumour size, vascular invasion, and satellite nodules) and is a key determinant of patient prognosis, with a strong and independent predictive value for early and overall tumour recurrence. Gene expression profiling has demonstrated that angiogenesis activation is a hallmark feature of MTM-HCC, with overexpression of both angiopoietin 2 (ANGPT2) and vascular endothelial growth factor A (VEGFA).
- | Journal: Glycation of Tie-2 Inhibits Angiopoietin-1 Signaling Activation and Angiopoietin-1-Induced Angiogenesis. (Pubmed Central) - Jul 17, 2022
Collectively, these data suggest that Tie-2 may be modified by AGEs in diabetes mellitus and that Tie-2 glycation inhibits Ang-1 signaling activation and Ang-1-induced angiogenesis. This may provide a novel mechanism for Ang-1/Tie-2 signal dysfunction and angiogenesis failure in diabetic ischaemic diseases.
- | Journal: Angiopoietin-like 3 Inhibition: New Kid on the Block? (Pubmed Central) - Jul 15, 2022
This may provide a novel mechanism for Ang-1/Tie-2 signal dysfunction and angiogenesis failure in diabetic ischaemic diseases. No abstract available
- | Journal: Angiopoietin-2 Inhibition of Thrombomodulin-Mediated Anticoagulation-A Novel Mechanism That May Contribute to Hypercoagulation in Critically Ill COVID-19 Patients. (Pubmed Central) - Jun 25, 2022
Using in vitro assays, we found that Angiopoietin-2 inhibited thrombomodulin-mediated anticoagulation and protein C activation in human donor plasma. Our data suggest a novel in vivo mechanism for Angiopoietin-2 in COVID-19-associated hypercoagulation, implicating that Angiopoietin-2 inhibitors may be effective in the treatment of hypercoagulation in severe COVID-19 infection.
- | Journal: Serum ANGPTL8 and ANGPTL3 as Predictors of Triglyceride Elevation in Adult Women. (Pubmed Central) - Jun 24, 2022
The association of ANGPTL3 with triglyceride levels is weaker than ANGPTL8 and depends on menopausal status. We suggest that the choice for the best efficient treatment of dyslipidemia with new inhibitors of angiopoietin-like proteins may depend on the menopausal status.
- | Preclinical, Journal, IO biomarker: Angiopoietin-1 protects against endotoxin-induced neonatal lung injury and alveolar simplification in mice. (Pubmed Central) - Jun 22, 2022
We suggest that the choice for the best efficient treatment of dyslipidemia with new inhibitors of angiopoietin-like proteins may depend on the menopausal status. Angiopoietin 1-based interventions may represent novel therapies for mitigating sepsis-induced lung injury and BPD in premature infants.
- ||||| Clinical: Finally out! Angiopoietin-2 Inhibition of Thrombomodulin-Mediated Anticoagulation—A Novel Mechanism That May Contribute to Hypercoagulation in Critically Ill COVID-19 Patients https://t.co/Ap3XmnoP9V Thanks to all great coauthors! @mhultstrom @SusanQuaggin @betsholtz (Twitter) - Jun 6, 2022
- Vabysmo (faricimab) / Roche
Personalized Treatment Interval (PTI) Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE and RHINE Trials of Faricimab in Diabetic Macular Edema (Main Room) - May 25, 2022 - Abstract #Macula2022Macula_84;
P3
Angiopoietin 1-based interventions may represent novel therapies for mitigating sepsis-induced lung injury and BPD in premature infants. Treat-and-extend–based PTI dosing in the phase 3 YOSEMITE/RHINE trials supports the extended durability of dual angiopoietin-2/VEGF-A inhibition with faricimab in patients with DME.
- | Journal: Linoleic Acid Induced Angiopoietin-Like Protein 4 Impairs Skeletal Muscle Differentiation. (Pubmed Central) - May 14, 2022
We further found that ANGPTL4 reduced β-catenin protein expression in nucleus, indicating that ANGPTL4 blocks β-catenin translocation into nucleus from cytoplasm, and it was restored with ANGPTL4 knockdown. Taken together, these results demonstrate that LA-induced ANGPTL4 inhibits skeletal muscle differentiation by suppressing Wnt/β-catenin signaling in C2C12 myoblasts.
- THROMBOMODULIN RESISTANCE: A NEW PROTHROMBOTIC PATHWAY IN COVID-19 () - May 13, 2022 - Abstract #EHA2022EHA_2559;
Conclusion Measurement of thrombin generation can be a powerful tool for the analysis of patients with COVID-19 on admission and thus for risk stratification. Increased thrombomodulin resistance is associated with the presence of an adverse event in patients and may be considered as new independent prognostic marker.
- | Journal: ANGPTL4: a new mode in the regulation of intravascular lipolysis. (Pubmed Central) - May 6, 2022
Increased thrombomodulin resistance is associated with the presence of an adverse event in patients and may be considered as new independent prognostic marker. Posttranslational regulation of LPL activity in the intravascular space is essential for the differential partitioning of TRLs across tissues and their lipolytic processing in response to nutritional cues.